Shasun Pharmaceuticals and Debiopharm Enter Into Licensing Agreement
News Apr 10, 2013
Shasun Pharmaceuticals Ltd and Debiopharm Group™ (Debiopharm) have entered into a licensing agreement for the manufacturing and commercialization of Huperzine-A.
Huperzine-A is a potent and reversible acetylcholinesterase inhibitor and clinical studies have shown a significant improvement in memory deficit and cognitive performance in patients with Alzheimer’s disease. Huperzine-A is commercially available through Shasun Pharmaceuticals.
According to the terms of the agreement, Shasun Pharmaceuticals Ltd will be able to use the Debiopharm technology for the manufacture of synthetic Huperzine-A under GMP quality conditions and commercialize it in pharmaceutical and nutraceutical markets.
The manufacturing technology involves a 10-stage chemical synthesis process including a complex chiral organometallic step as a key transformation of the Huperzine-A structure.
The synthesis is a result of a joint collaboration between Shasun’s research centers in Chennai and the UK.
This technology was recently recognized and awarded at the North East of England Process Industry Cluster (NEPIC), Innovation Awards in 2012.
NEPIC is a stand-alone company created to represent the 500+ Pharmaceutical, Biotechnology, Specialty Chemical, Polymer & Rubber, Petrochemical & Commodity Chemical companies based in the North East of England.
Commenting on the agreement, Dr Mauvernay, President and founder of Debiopharm Group™ said, “We are delighted to continue our collaboration with Shasun Pharmaceuticals Ltd. Clinical studies have demonstrated the drug to enable significant improvement in both memory deficit and cognitive performance and we are excited to have the opportunity to add value to this technology while contributing to improve people’s quality of life.”
Dr Michel Spagnol, President of Shasun Pharmaceuticals Ltd added, “We are very proud of this achievement, resulting from a very close collaboration with Debiopharm. It underlines our commitment to delivering cutting-edge science in all our processes through our global research and development network.”
Diabetic Ketoacidosis Assay Collaboration Between Ortho Clinical Diagnostics and EKF DiagnosticsNews
EKF’s Beta-Hydroxybutyrate LiquiColor® Assay for detection of predominant ketone body now available on Ortho’s VITROS® 4600 Chemistry System and VITROS® 5600 Integrated System.READ MORE
Key Cancer-Linked Proteins Thought to be ‘Undruggable’ Until NowNews
A new study published in Nature, conducted by an alliance between industry and academia involving the University of Liverpool, highlights a new approach to targeting key cancer-linked proteins, thought to be ‘undruggable’.READ MORE